Literature DB >> 30169779

Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs.

Taisia Shmushkovich1, Kathryn R Monopoli1, Diana Homsy1, Dmitriy Leyfer1,2, Monica Betancur-Boissel1, Anastasia Khvorova3, Alexey D Wolfson1.   

Abstract

Progress in oligonucleotide chemistry has produced a shift in the nature of siRNA used, from formulated, minimally modified siRNAs, to unformulated, heavily modified siRNA conjugates. The introduction of extensive chemical modifications is essential for conjugate-mediated delivery. Modifications have a significant impact on siRNA efficacy through interference with recognition and processing by RNAi enzymatic machinery, severely restricting the sequence space available for siRNA design. Many algorithms available publicly can successfully predict the activity of non-modified siRNAs, but the efficiency of the algorithms for designing heavily modified siRNAs has never been systematically evaluated experimentally. Here we screened 356 cholesterol-conjugated siRNAs with extensive modifications and developed a linear regression-based algorithm that effectively predicts siRNA activity using two independent datasets. We further demonstrate that predictive determinants for modified and non-modified siRNAs differ substantially. The algorithm developed from the non-modified siRNAs dataset has no predictive power for modified siRNAs and vice versa. In the context of heavily modified siRNAs, the introduction of chemical asymmetry fully eliminates the requirement for thermodynamic bias, the major determinant for non-modified siRNA efficacy. Finally, we demonstrate that in addition to the sequence of the target site, the accessibility of the neighboring 3' region significantly contributes to siRNA efficacy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30169779      PMCID: PMC6237813          DOI: 10.1093/nar/gky745

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  45 in total

1.  Design of a genome-wide siRNA library using an artificial neural network.

Authors:  Dieter Huesken; Joerg Lange; Craig Mickanin; Jan Weiler; Fred Asselbergs; Justin Warner; Brian Meloon; Sharon Engel; Avi Rosenberg; Dalia Cohen; Mark Labow; Mischa Reinhardt; François Natt; Jonathan Hall
Journal:  Nat Biotechnol       Date:  2005-07-17       Impact factor: 54.908

2.  Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

Authors:  Michael A Collingwood; Scott D Rose; Lingyan Huang; Chris Hillier; Mohammad Amarzguioui; Merete T Wiiger; Harris S Soifer; John J Rossi; Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-06

3.  Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye.

Authors:  Michael Byrne; Radouil Tzekov; Yi Wang; Amanda Rodgers; James Cardia; Glenna Ford; Katherine Holton; Lakshmipathi Pandarinathan; Jennifer Lapierre; William Stanney; Karen Bulock; Sharon Shaw; Lyn Libertine; Kevin Fettes; Anastasia Khvorova; Shalesh Kaushal; Pamela Pavco
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-01       Impact factor: 2.671

4.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA.

Authors:  Charles R Allerson; Namir Sioufi; Russell Jarres; Thazha P Prakash; Nishant Naik; Andres Berdeja; Lisa Wanders; Richard H Griffey; Eric E Swayze; Balkrishen Bhat
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

5.  Visualization of self-delivering hydrophobically modified siRNA cellular internalization.

Authors:  Socheata Ly; Deanna M Navaroli; Marie-Cécile Didiot; James Cardia; Lakshmipathi Pandarinathan; Julia F Alterman; Kevin Fogarty; Clive Standley; Lawrence M Lifshitz; Karl D Bellve; Matthieu Prot; Dimas Echeverria; Silvia Corvera; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

6.  Impact of target mRNA structure on siRNA silencing efficiency: A large-scale study.

Authors:  Joseph A Gredell; Angela K Berger; S Patrick Walton
Journal:  Biotechnol Bioeng       Date:  2008-07-01       Impact factor: 4.530

7.  Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of Its Nucleic Acid Guides.

Authors:  William E Salomon; Samson M Jolly; Melissa J Moore; Phillip D Zamore; Victor Serebrov
Journal:  Cell       Date:  2015-07-02       Impact factor: 41.582

8.  Competition for RISC binding predicts in vitro potency of siRNA.

Authors:  Erich Koller; Stephanie Propp; Heather Murray; Walter Lima; Balkrishen Bhat; Thaza P Prakash; Charles R Allerson; Eric E Swayze; Eric G Marcusson; Nicholas M Dean
Journal:  Nucleic Acids Res       Date:  2006-08-31       Impact factor: 16.971

Review 9.  Advances in the delivery of RNA therapeutics: from concept to clinical reality.

Authors:  James C Kaczmarek; Piotr S Kowalski; Daniel G Anderson
Journal:  Genome Med       Date:  2017-06-27       Impact factor: 11.117

10.  Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma.

Authors:  Maarten A Ligtenberg; Yago Pico de Coaña; Taisia Shmushkovich; Yuya Yoshimoto; Iva Truxova; Yuan Yang; Monica Betancur-Boissel; Alexey V Eliseev; Alexey D Wolfson; Rolf Kiessling
Journal:  Mol Ther       Date:  2018-04-13       Impact factor: 11.454

View more
  15 in total

1.  Programmable manipulation of oligonucleotide-albumin interaction for elongated circulation time.

Authors:  Cai Yang; Haitao Zhao; Yang Sun; Cheng Wang; Xinyao Geng; Ruowen Wang; Lumin Tang; Da Han; Jianjun Liu; Weihong Tan
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

2.  RNAi-based modulation of IFN-γ signaling in skin.

Authors:  Qi Tang; Jacquelyn Sousa; Dimas Echeverria; Xueli Fan; Ying-Chao Hsueh; Khashayar Afshari; Nicholas MeHugh; David A Cooper; Lorenc Vangjeli; Kathryn Monopoli; Ken Okamura; Annabelle Biscans; Adam Clauss; John E Harris; Anastasia Khvorova
Journal:  Mol Ther       Date:  2022-04-27       Impact factor: 12.910

Review 3.  Small nucleic acids and the path to the clinic for anti-CRISPR.

Authors:  Christopher L Barkau; Daniel O'Reilly; Seth B Eddington; Masad J Damha; Keith T Gagnon
Journal:  Biochem Pharmacol       Date:  2021-02-27       Impact factor: 6.100

4.  2'-O-Methyl at 20-mer Guide Strand 3' Termini May Negatively Affect Target Silencing Activity of Fully Chemically Modified siRNA.

Authors:  Sarah M Davis; Jacquelyn Sousa; Lorenc Vangjeli; Matthew R Hassler; Dimas Echeverria; Emily Knox; Anton A Turanov; Julia F Alterman; Anastasia Khvorova
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-15       Impact factor: 8.886

Review 5.  Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy.

Authors:  Mouldy Sioud
Journal:  Cancers (Basel)       Date:  2019-02-03       Impact factor: 6.639

Review 6.  Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery.

Authors:  Wanyi Tai
Journal:  Molecules       Date:  2019-06-13       Impact factor: 4.411

Review 7.  siRNA Targeting and Treatment of Gastrointestinal Diseases.

Authors:  Rachel Chevalier
Journal:  Clin Transl Sci       Date:  2019-08-05       Impact factor: 4.689

Review 8.  Editorial focus: understanding off-target effects as the key to successful RNAi therapy.

Authors:  Rafal Bartoszewski; Aleksander F Sikorski
Journal:  Cell Mol Biol Lett       Date:  2019-12-09       Impact factor: 5.787

9.  Introducing an In Vitro Liver Stability Assay Capable of Predicting the In Vivo Pharmacodynamic Efficacy of siRNAs for IVIVC.

Authors:  Babak Basiri; Fang Xie; Bin Wu; Sara C Humphreys; Julie M Lade; Mai B Thayer; Pam Yamaguchi; Monica Florio; Brooke M Rock
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-10       Impact factor: 8.886

10.  Postsynthetic On-Column 2' Functionalization of RNA by Convenient Versatile Method.

Authors:  Olga A Krasheninina; Veniamin S Fishman; Alexander A Lomzov; Alexey V Ustinov; Alya G Venyaminova
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.